Lonza entered a long-term, strategic collaboration for bioconjugation with a global biopharma company, under which, Lonza will construct two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates (ADCs) at its Visp (CH) site.   As part of Lonza’s Ibex Dedicate model, two bioconjugation suites totaling 1500m2 of active manufacturing space will be built out within a pre-existing shell. The new suites will also benefit from established quality control (QC)...